APA (7th ed.) Citation

NC, G., A, C., G, A., W, M., B, F., JA, P., . . . R, S. (2026). Lipoxin A4 (LXA4) versus Nanolipoxin A4 (Nano-LXA4) for osteosarcoma. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 226, 115132. https://doi.org/10.1016/j.ejpb.2026.115132

Chicago Style (17th ed.) Citation

NC, Gomes-da-Silva, et al. "Lipoxin A4 (LXA4) Versus Nanolipoxin A4 (Nano-LXA4) for Osteosarcoma." European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V 226 (2026): 115132. https://doi.org/10.1016/j.ejpb.2026.115132.

MLA (9th ed.) Citation

NC, Gomes-da-Silva, et al. "Lipoxin A4 (LXA4) Versus Nanolipoxin A4 (Nano-LXA4) for Osteosarcoma." European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, vol. 226, 2026, p. 115132, https://doi.org/10.1016/j.ejpb.2026.115132.